SV2015004997A - Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento - Google Patents

Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento

Info

Publication number
SV2015004997A
SV2015004997A SV2015004997A SV2015004997A SV2015004997A SV 2015004997 A SV2015004997 A SV 2015004997A SV 2015004997 A SV2015004997 A SV 2015004997A SV 2015004997 A SV2015004997 A SV 2015004997A SV 2015004997 A SV2015004997 A SV 2015004997A
Authority
SV
El Salvador
Prior art keywords
tablets
during storage
good stability
stability during
improved acceptance
Prior art date
Application number
SV2015004997A
Other languages
English (en)
Inventor
Venkata- Rangarao Kanikanti
HANS- JÃœRGEN HAMANN
Georg Schulte
Patrick Billian
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of SV2015004997A publication Critical patent/SV2015004997A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPRIMIDOS PARA ANIMALES QUE TIENEN UNA ACEPTACIÓN MEJORADA Y BUENA ESTABILIDAD DURANTE EL ALMACENAMIENTO
SV2015004997A 2012-12-19 2015-06-16 Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento SV2015004997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12198101 2012-12-19
PCT/EP2013/076878 WO2014095845A1 (de) 2012-12-19 2013-12-17 Tabletten mit verbesserter akzeptanz und guter lagerstabilität

Publications (1)

Publication Number Publication Date
SV2015004997A true SV2015004997A (es) 2017-05-12

Family

ID=47458712

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2015004997A SV2015004997A (es) 2012-12-19 2015-06-16 Comprimidos que tienen aceptacion mejorada y buena estabilidad durante el almacenamiento

Country Status (23)

Country Link
US (2) US10543170B2 (es)
EP (1) EP2934490B1 (es)
JP (1) JP6393274B2 (es)
KR (1) KR102253847B1 (es)
CN (1) CN105025885B (es)
AU (1) AU2013361760B2 (es)
CA (1) CA2895254C (es)
CL (1) CL2015001685A1 (es)
CR (1) CR20150321A (es)
DO (2) DOP2015000150A (es)
EC (1) ECSP15026203A (es)
ES (1) ES2848394T3 (es)
HK (1) HK1216856A1 (es)
IL (1) IL239297B (es)
MX (1) MX2015007640A (es)
MY (1) MY175703A (es)
NZ (1) NZ708741A (es)
PH (1) PH12015501390A1 (es)
PT (1) PT2934490T (es)
RU (1) RU2693005C2 (es)
SV (1) SV2015004997A (es)
UA (1) UA118748C2 (es)
WO (1) WO2014095845A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102253847B1 (ko) * 2012-12-19 2021-05-21 바이엘 애니멀 헬스 게엠베하 향상된 수용성 및 우수한 저장 안정성을 가지는 정제
CN106580896A (zh) * 2016-12-07 2017-04-26 成都乾坤动物药业股份有限公司 一种非班太尔分散片及其制备方法
CA3046275A1 (en) * 2016-12-09 2018-06-14 Bayer Animal Health Gmbh Pharmaceutical preparation and method for its manufacture
US11896594B2 (en) * 2018-09-05 2024-02-13 Zoetis Services Llc Palatable antiparasitic formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3705227A1 (de) 1987-02-19 1988-09-01 Bayer Ag Anthelminthische wirkstoffkombinationen
FR2715803B3 (fr) 1994-02-04 1996-05-10 Attali Jean Claude Leurre et procédé facilitant la prise de médicaments par certains animaux et en particulier par les chiens.
DE670160T1 (de) 1994-03-01 1996-03-14 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
DE19520275A1 (de) 1995-06-02 1996-12-05 Bayer Ag Endoparasitizide Mittel
US20040180034A1 (en) * 2003-03-10 2004-09-16 Lyn Hughes Anthelmintic resinates and a method for their preparation
DE10328666A1 (de) 2003-06-26 2005-01-13 Bayer Healthcare Ag Tabletten enthaltend Geschmacks-und/oder Aromastoffe
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
GB2407498B (en) 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE102004011512B4 (de) * 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US7348027B2 (en) 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
JP2007269716A (ja) * 2006-03-31 2007-10-18 Sato Pharmaceutical Co Ltd 塩酸セチリジン含有粒子
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010132286A1 (en) 2009-05-12 2010-11-18 Wyeth Llc Orally administered tablet formulation of an antianxiolytic compound
GB2475701B (en) * 2009-11-26 2011-10-19 Michael Hilary Burke A process for the preparation of an orally administered anthelmintic unit dose tablet
CN103200930A (zh) 2010-10-12 2013-07-10 拜耳知识产权有限责任公司 非淀粉基软咀嚼品
TR201902125T4 (tr) * 2012-02-06 2019-03-21 Merial Inc Si̇stemi̇k olarak etki̇ eden akti̇f ajanlari i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
KR102253847B1 (ko) * 2012-12-19 2021-05-21 바이엘 애니멀 헬스 게엠베하 향상된 수용성 및 우수한 저장 안정성을 가지는 정제
GB201413832D0 (en) * 2014-08-05 2014-09-17 Tate & Lyle Ingredients Starch compositions useful for thickening aqueous liquids

Also Published As

Publication number Publication date
EP2934490B1 (de) 2020-08-12
JP6393274B2 (ja) 2018-09-19
DOP2020000031A (es) 2020-02-28
PT2934490T (pt) 2020-12-15
DOP2015000150A (es) 2015-07-15
KR102253847B1 (ko) 2021-05-21
PH12015501390A1 (en) 2015-09-02
AU2013361760B2 (en) 2018-07-05
HK1216856A1 (zh) 2016-12-09
IL239297B (en) 2021-10-31
KR20150094643A (ko) 2015-08-19
EP2934490A1 (de) 2015-10-28
US20150342889A1 (en) 2015-12-03
JP2016503767A (ja) 2016-02-08
CN105025885A (zh) 2015-11-04
CR20150321A (es) 2015-07-29
US20200113823A1 (en) 2020-04-16
RU2693005C2 (ru) 2019-07-01
AU2013361760A1 (en) 2015-07-09
ES2848394T3 (es) 2021-08-09
NZ708741A (en) 2019-11-29
MX2015007640A (es) 2015-09-23
US10543170B2 (en) 2020-01-28
MY175703A (en) 2020-07-06
US11147764B2 (en) 2021-10-19
CN105025885B (zh) 2022-04-08
WO2014095845A1 (de) 2014-06-26
RU2015129310A (ru) 2017-01-24
UA118748C2 (uk) 2019-03-11
CA2895254A1 (en) 2014-06-26
CL2015001685A1 (es) 2015-10-23
CA2895254C (en) 2021-01-26
ECSP15026203A (es) 2016-01-29
IL239297A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
DK3030227T3 (da) Vedvarende frigivelses-doseringsformer for en jak1-inhibitor
UY34970A (es) Una Plataforma Elevable para Espectáculos Acuáticos
DOP2020000031A (es) Comprimidos que tienen aceptación mejorada y buena estabilidad durante el almacenamiento
BR112013028281A2 (pt) compostos e composições para inibição de nampt
CO6980640A2 (es) Implemento para el cuidado oral empacado
ECSP13013074A (es) Nuevos derivados de piridina
CR20130406A (es) Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9
CO6990725A2 (es) Composiciones blanqueadoras para el cuidado oral
CO6990720A2 (es) Composiciones que comprenden galatos y galamidas
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
CO7151512A2 (es) Inhibidores del nampt
CO6930364A2 (es) Composiciones farmaceúticas que comprenden 40-o-(2-hidroxi) etil - rapamicina
CR20150204A (es) Nuevos derivados de piridina
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
BR112015003294A2 (pt) caldeira de armazenamento
CO7200262A2 (es) Nueva dosificación y formulación
BR112013027403A2 (pt) composições que compreendem uma antimetabólito de glicose e selênio
CL2015001645A1 (es) Agentes herbicidas que contienen aclonifeno
DK3069733T3 (da) Ny acetaminophenforbindelsessammensætning uden bivirkninger for leveren
DK2919761T3 (da) Fast doseringsform omfattende mikroniseret cytisin
DK2879664T3 (da) Transdermal formulering indeholdende cox-inhibitorer
DK2934510T3 (da) Lfa-1-inhibitorformuleringer
FR3012814B1 (fr) Composition polymere comprenant et liberant un compose actif odorant
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
ITMI20130336U1 (it) Dispositivo di contenimento di un cavo di una linea vita